Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sammenligning af den Bedste Metode til Måling af Anti-Xa-aktivitet hos Børn, der Modtager Ufraktioneret Heparin på Hjerteintensiv (COMPAXE-HNF) (COMPAXE-HNF)

18. september 2026 opdateret af: Centre Hospitalier Universitaire de la Réunion

Sammenligning af den bedste metode til måling af anti-Xa-aktivitet hos børn, der modtager ufraktioneret heparin på hjerteintensiv (COMPAXE-HNF)

This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC. The results will be compared to a "gold standard" sample taken from an arterial catheter (KTA) whithout UFH. The objective is to identify a more reliable method for monitoring UFH, thereby reducing the risk of bleeding or thrombosis in these patients.

Studieoversigt

Detaljeret beskrivelse

  • Scientific Justification: UFH is widely used in pediatric cardiac intensive care for its short half-life and availability of an antidote. However, monitoring its effect via anti-Xa activity is challenging. The standard method of sampling from a CVC is known to be prone to heparin contamination, leading to inaccurate results (over- or under-anticoagulation). This lack of precision can lead to dangerous complications like major bleeding or thrombotic events. As studies by Palermo et al. (1980) and Bauman et al. (2012) have shown, the unreliability of CVC samples justifies the search for a safer alternative. The arterial catheter (KTA) provides a contamination-free "gold standard," making it the ideal comparison for evaluating the more reliable sampling method.
  • Procedure: The study will compare two CVC sampling methods (a standard flush protocol and a new experimental method) against the gold standard (KTA sampling without UFH)
  • Follow-up: The study will be conducted over three consecutive days. Each day, three sets of blood samples will be collected every 6 hours per patient (KTA, standard CVC, and experimental CVC).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

22

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 dag til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Minors aged 0 to 17 inclusive
  • Weight greater than or equal to 3.5 kg
  • Admitted to resuscitation or congenital cardiac intensive care
  • Requiring treatment with unfractionated heparin at curative doses administered via central venous access
  • Equipped with a central arterial and venous catheter
  • Affiliated with or beneficiary of a social security scheme
  • Free, informed, and written consent signed by one of the two representatives of parental authority and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion Criteria:

  • Newborns < 37 weeks gestation
  • Patients treated by a humanitarian organization

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: anti-Xa activity monitoring

All patients included in the study

Each patient included in the study will have a series of three samples taken every 4 hours for 3 days:

  • Sample taken from a non-heparinized arterial catheter (Gold Standard), performed as part of routine care: Method ①
  • Sample taken from a central venous catheter without stopping the HNF: Method ②
  • Sampling from a central venous catheter with an HNF pause: Method ③

At each anti-Xa activity check in the included patients, the nurse will take the 3 blood samples.

The order in which samples ② and ③ are taken will be determined by randomization.

Each patient will have, each time that anti-Xa activity needs to be measured, three successive samples taken:

  • Sample taken from a non-heparinized arterial catheter (gold standard), performed as part of routine care: Method ①
  • Sample taken from a central venous catheter without stopping the HNF: Method ②
  • Sample from central venous catheter with HNF pause: Method ③

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measurement of anti-Xa activity (in IU/mL) from two samples (with and without HNF pause) taken from the central venous line where HNF is administered, compared to a sample taken from a non-heparinized arterial catheter (i.e., gold standard).
Tidsramme: "From enrollment to the end of study at 72hours"

Anti-Xa activity and APTT measurements will be performed at the university hospital's central laboratory, which guarantees the consistency of the reagents, automated systems, and techniques used.

The recommended therapeutic target is between 0.3 and 0.6 IU/mL.

"From enrollment to the end of study at 72hours"

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measurement of APTT from two samples (with and without HNF pause) taken from the central venous line where HNF is administered, compared to a sample taken from a non-heparinized arterial catheter (i.e., gold standard).
Tidsramme: "From enrollment to the end of study at 72 hours"

Activated partial thromboplastin time (APTT):

Mainly used in the United States and in some French intensive care units, the APTT provides an overall assessment of the activity of several coagulation factors: factor I (or fibrinogen), factor II (or prothrombin), factor V, factor VIII, factor IX, factor X, factor XI, and factor XII. (Figure 1) The APTT is a measure of blood clotting time. It is expressed as a ratio between the patient's APTT and a "control" APTT, which is that of the laboratory. It is expressed in seconds.

Normal values for the patient APTT/control APTT ratio are between 0.80 s and 1.20 s.

  • Above this range: the risk of bleeding increases.
  • Below this range: treatment is ineffective, with a risk of clot formation.
"From enrollment to the end of study at 72 hours"
Measurement of APTT and anti-Xa activity (in IU/mL) from a sample taken from a non-heparinized arterial catheter (i.e., gold standard)
Tidsramme: From enrollment to the end of study at 72 hours

The TCA measurement is performed in the same way.

From enrollment to the end of study at 72 hours

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. november 2029

Studieafslutning (Anslået)

1. november 2029

Datoer for studieregistrering

Først indsendt

16. januar 2026

Først indsendt, der opfyldte QC-kriterier

16. januar 2026

Først opslået (Faktiske)

26. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner